The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.
December 6th 2023
A trial comparing baricitinib against placebo in people with new-onset type 1 diabetes suggests use could contribute to the preservation of β-cell function.
December 6th 2023
The study did not find an association between glycemic parameters and flow-mediated dilation, but they did find associations between lower sleep efficiency with poorer glycemic control, insulin resistance, estimated glucose disposal rate, and HbA1C.
Rajiv Agarwal, MD, MS, provides insight into an analysis from ASN Kidney Week 2023 detailing the effect of early albuminuria reduction on risk of adverse kidney and cardiovascular outcomes in people with T2D and chronic kidney disease.
In this episode, hosts discuss the FDA clearance of the Omnipod 5 App for iPhones and a pair of studies examining use of automated insulin delivery systems.
This endocrine case report from Brady Pregerson, MD features a 32-year-old female with a history of polycystic ovary syndrome and diabetes who presents to the emergency department for sudden trouble swallowing, confusion, and shakiness. Can you determine the correct diagnosis?
In this episode, hosts discuss the results of SURMOUNT-3 and SURMOUNT-4 as well as how it might help inform use of tirzepatide if approved by the US Food and Drug Administration for chronic weight management.
In this episode, hosts discuss data from the PROTECT trial, which examined the effects of teplizumab on beta-cell function in patients with newly diagnosed type 1 diabetes.
In the PROTECT trial, teplizumab preserved β-cell function in newly diagnosed type 1 diabetes patients, slowing the decline of C-peptide levels, but key secondary endpoints, such as time in range and HbA1c, showed numerical trends without statistical significance.
Despite access to care and health insurance, Hispanic and non-Hispanic Black individuals with diabetes experience poorer glycemic control compared to non-Hispanic White counterparts, revealing persistent racial disparities in healthcare.
On October 10, 2023, Novo Nordisk announced they would be stopping the FLOW trial, which examined the effects of semaglutide 1.0 mg on kidney outcomes in type 2 diabetes, due to early efficacy based on an interim analysis of the trial.
Compared to placebo, patients using once-daily oral HU6 100 mg, HU6 300 mg, and HU6 450 mg experienced significant changes in liver fat, volume, and whole-body adiposity after 61 days of treatment.
A new study from Sweden is calling attention to disproportionate increases in psychotropic medication use among young people with type 1 diabetes relative to their counterparts without type 1 diabetes.